Development and Commercialization of the New Peptide Drug Manufacturing Technology SYNCSOL™
First written in FY2022. 3 of 4 entries say "Advanced", first in FY2023. Latest entry: FY2026.
No other company in this theme has enough history to compare yet.
- FY2026AdvancedAnnual report
「Specifically, we have completed the installation of containment equipment capable of manufacturing quantities ranging from 100 g to several kilograms and are working on the development of new highly potent pharmaceutical APIs, as well as」
The installation of containment equipment capable of handling quantities from 100 g to several kilograms of highly potent pharmaceutical APIs has been completed, and the company is advancing new API development and customer solutions using SYNCSOL®. - FY2024AdvancedAnnual report
「With the aim of commercializing SYNCSOL®, an affordable, high-quality manufacturing technology for linear and cyclic peptides, we are developing applications for APIs and related medical materials using these technologies. We will apply this technology through collaboration with PeptiStar Co., Ltd. and expand the business by solving customers' challenges.」
SYNCSOL® is being applied to APIs of linear and cyclic peptide drugs and related medical materials, with commercialization being advanced through collaboration with PeptiStar and solutions to customers' challenges. - FY2023AdvancedAnnual report
「With the aim of commercializing SYNCSOL®, an affordable, high-quality manufacturing technology for linear and cyclic peptides, we are developing applications for APIs of linear and cyclic peptide drugs and related medical materials. We will apply this technology through collaboration with PeptiStar Co., Ltd. and expand the business by solving customers' challenges.」
For SYNCSOL®, the company specified its commercialization approach, including large-scale manufacturing of linear and cyclic peptides, collaboration with PeptiStar, and proposing solutions to customers' challenges. - FY2022First statedAnnual report
「We developed the new SYNCSOL™ manufacturing technology to supply peptide drug APIs. This enables the production of high-quality peptides. We will seek to expand the business by using this technology to propose solutions for social issues, including orphan drugs.」
The company is seeking to expand the business by developing the new SYNCSOL™ manufacturing technology, producing high-quality peptides, and proposing solutions for orphan drugs and other areas.